Core Thesis - Viking Therapeutics (NASDAQ:VKTX) is a clinical-stage biotechnology company focused on developing novel treatments for metabolic and endocrinology disorders, with its leading program VK2735 targeting obesity through dual agonism of GLP-1 and GIP receptors [2][3] VK2735 Development - VK2735 has two formulations: a subcutaneous weekly injection nearing the end of Phase II trials and a daily oral tablet expected to enter Phase II in Q4 2024 [2][3][10] - The subcutaneous formulation has shown promising results, achieving a weight loss of up to 14.7% from baseline in 13 weeks, with a low incidence of severe treatment-emergent adverse events [8][9] - The oral formulation has demonstrated a weight loss of up to 5.3% from baseline in Phase I trials, with good tolerability and safety results [10][12] Competitive Landscape - The obesity drug market is currently dominated by Eli Lilly and Novo Nordisk, but VK2735 could be the first oral GLP-1/GIP dual agonist if approved [3][13] - Other competitors include Amgen, AstraZeneca, and Roche, with several candidates in Phase II or above, indicating a highly competitive environment [13][14] - VK2735's clinical performance is favorable compared to competitors, with the potential for significant market impact if it successfully navigates regulatory approval [15][22] Financial Overview - Viking reported $942 million in cash and equivalents as of June 2024, a 139.8% increase from the previous year, providing a cash runway for approximately four years [16][17] - The company incurred a net loss of $49.606 million in H1 2024, with anticipated costs for the Phase III trial of VK2735 estimated at $300 million [17][18] Valuation and Market Performance - Viking's shares have increased by 245% year-to-date, with a current price around $63, showing signs of recovery after recent market fluctuations [18][19] - Analysts have a consensus rating of "Strong Buy" for VKTX, with a projected upside potential of 77% over the next twelve months [19][20]

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 28, 2024) - Investorideas.com, a go-to investing platform covering health and wellness and biotech stocks issues a snapshot looking at news and developments for the global GLP-1 receptor agonist market, featuring new player in the market, Integrated Ventures, Inc. (OTCQB: INTV). Read the full article at Investorideas.com https://www.investorideas.com/News/2024/biotech/08280GLP-1.asp According to Research and Markets, The global GLP-1 ...

TAMPA, Fla. , Aug. 28, 2024 /PRNewswire/ -- Integrated Ventures, Inc. (OTCQB: INTV), a diversified portfolio holdings company, is excited to announce its strategic entry into the rapidly expanding health and wellness sector. The initial phase of this transition will be led by the newly established subsidiary, MedWell USA, LLC, which will serve as a B2B Procurement Agent for a variety of pharmaceutical products, with a particular focus on the booming medical weight loss and GLP-1 markets. MedWell USA will be ...

SUNNYVALE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Ozempic®, Wegovy® and compounded semaglutide through a weight loss program on its telehealth platform, providing consumers with access to affordable weight management care through a convenient subscription-based model. If prescribed, Lemonaid Health patients will now have access to once-weekly injectable GLP-1 medication offerings ...

Ozempic remains on top in the GLP-1 drug market -- but for how long? The anti-obesity drug market could one day be worth $100 billion. It's a massive opportunity in healthcare, and two companies that are leaders in that space today are Eli Lilly (LLY 0.23%) and Novo Nordisk (NVO 1.42%). Unsurprisingly, these are also two of the most valuable healthcare companies in the world right now. They have been rivals for decades, and the growing popularity of their respective glucagon-like peptide 1 (GLP1) drugs ensu ...

SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, has started screening patients for a Phase 2 clinical trial (CBeyondTM) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. The study will assess the ability of nimacimab as a nextgeneration weight loss therapeutic to safely and effectively reduce weight in patients w ...

SAN DIEGO, Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is raising awareness of the potential impact these medications may have on the effectiveness of oral contraceptives. With an increasing number of women turning to GLP-1 medications for weight management and glycemic control, the need for reliable non-oral contraceptive options has never been more acute. GLP-1 receptor ...

● . ● | --- | --- | |---------------------------------------------------|-------| | | | | Defence Investigates the Application of the Accum | | | Hydrogel Technology to Deliver GLP-1 in Order to | | | Increase the Treatment Efficacy of Diabetes and | | August 19, 2024 9:27 AM EDT | Source: Defence Therapeutics Inc. Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company ...

Mounjaro and Zepbound are likely to be Eli Lilly's top two products in the very near future. For a top drugmaker like Eli Lilly (LLY -1.01%), developing new drugs is key to ensuring that its business continues to grow. Patents don't last forever, so continuing to innovate is the only surefire way to be successful and remain a top company in the healthcare industry. In the past couple of years, the company has obtained approvals for multiple new products, including Mounjaro for diabetes, Zepbound for weight ...

TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is offering its novel BRAIN AGE® Brain Health AI Platform ("BRAIN AGE®") as a clinical tool for investigating the impact of weight loss drugs, such as Semaglutide, on brain function. In a recently published study, Semaglutide, a GLP-1 receptor agonist that has been approved by the FDA and is currently marketed in vari ...